BC Extra | Dec 21, 2019
Company News

Dec. 20 Company Quick Takes: Genmab partners with CureVac; plus pair of Biogen deals, Ionis, Akcea-Novartis, Paratek and J&J-Taris

CureVac, Genmab to develop RNA-encoded antibody  Genmab A/S (NASDAQ:GMAB; CSE:GMAB) and CureVac AG have partnered to discover an mRNA-encoded antibody candidate to treat cancer. Genmab will pay $10 million up front and invest €20 million...
BC Extra | Jun 24, 2019
Company News

Management Tracks: Kress to succeed Moroney at MorphoSys; plus Sutro, Entasis and more

MorphoSys AG (Xetra:MOR; NASDAQ:MOR) said Jean-Paul Kress will take over as CEO from Simon Moroney, who in February announced his decision not to renew his contract as a member of MorphoSys’ management board, on Sept....
BC Week In Review | Oct 19, 2018
Clinical News

Taris' TAR-302 reduces daily incontinence episodes by 75% in Phase Ib

Taris Biomedical LLC (Lexington, Mass.) reported Phase Ib data in August showing that TAR-302 reduced mean daily incontinence episodes by 75% at day 42 in idiopathic overactive bladder (OAB) patients who were experiencing an average...
BC Week In Review | Dec 22, 2017
Financial News

Drug delivery company Taris raises $25M series B

Drug delivery company Taris Biomedical LLC (Lexington, Mass.) raised $25 million in a series B round on Dec. 21 led by Yonghua Capital. New investors Bristol-Myers Squibb Co. (NYSE:BMY) and Norma Investments also participated, as...
BC Extra | Dec 21, 2017
Financial News

Taris raises $25M series B

Drug delivery company Taris Biomedical LLC (Lexington, Mass.) raised $25 million in a series B round Thursday led by Yonghua Capital. New investors Bristol-Myers Squibb Co. (NYSE:BMY) and Norma Investments also participated, as did existing...
BC Week In Review | Jan 6, 2017
Clinical News

TAR-200: Preliminary Ph Ib data

Preliminary data from 10 patients with muscle invasive bladder cancer in an open-label, U.S. Phase Ib trial showed that TAR-200 inserted into the bladder during days 1-7 and days 21-28 following initial transurethral resection of...
BC Week In Review | Aug 15, 2016
Clinical News

GemRIS: Phase Ib started

Taris began an open-label, European Phase Ib trial to evaluate TAR-200 inserted into the bladder for 7 days at days 0 and 21 in up to 30 patients with intermediate-risk NMIBC before transurethral resection of...
BC Week In Review | Jul 25, 2016
Clinical News

GemRIS: Phase Ib started

Taris began an open-label, U.S. Phase Ib trial to evaluate TAR-200 inserted into the bladder for 7 days at days 0 and 21 in up to 20 patients before radical cystectomy. Taris Biomedical LLC , Lexington,...
BioCentury | Feb 22, 2016
Finance

Investing upstream

After a decade of focusing on public investments and later adding private investments to its remit, RA Capital is getting into the business of starting companies from whole cloth. The firm thinks having a dedicated...
BC Week In Review | Nov 2, 2015
Financial News

Taris Biomedical completes venture financing

Taris Biomedical LLC , Lexington, Mass.   Business: Cancer, Genitourinary, Drug delivery   Date completed: 2015-10-27   Type: Venture financing   Raised: $32 million   Investors: Flagship Ventures; Polaris Partners; RA Capital Management  ...
Items per page:
1 - 10 of 31
BC Extra | Dec 21, 2019
Company News

Dec. 20 Company Quick Takes: Genmab partners with CureVac; plus pair of Biogen deals, Ionis, Akcea-Novartis, Paratek and J&J-Taris

CureVac, Genmab to develop RNA-encoded antibody  Genmab A/S (NASDAQ:GMAB; CSE:GMAB) and CureVac AG have partnered to discover an mRNA-encoded antibody candidate to treat cancer. Genmab will pay $10 million up front and invest €20 million...
BC Extra | Jun 24, 2019
Company News

Management Tracks: Kress to succeed Moroney at MorphoSys; plus Sutro, Entasis and more

MorphoSys AG (Xetra:MOR; NASDAQ:MOR) said Jean-Paul Kress will take over as CEO from Simon Moroney, who in February announced his decision not to renew his contract as a member of MorphoSys’ management board, on Sept....
BC Week In Review | Oct 19, 2018
Clinical News

Taris' TAR-302 reduces daily incontinence episodes by 75% in Phase Ib

Taris Biomedical LLC (Lexington, Mass.) reported Phase Ib data in August showing that TAR-302 reduced mean daily incontinence episodes by 75% at day 42 in idiopathic overactive bladder (OAB) patients who were experiencing an average...
BC Week In Review | Dec 22, 2017
Financial News

Drug delivery company Taris raises $25M series B

Drug delivery company Taris Biomedical LLC (Lexington, Mass.) raised $25 million in a series B round on Dec. 21 led by Yonghua Capital. New investors Bristol-Myers Squibb Co. (NYSE:BMY) and Norma Investments also participated, as...
BC Extra | Dec 21, 2017
Financial News

Taris raises $25M series B

Drug delivery company Taris Biomedical LLC (Lexington, Mass.) raised $25 million in a series B round Thursday led by Yonghua Capital. New investors Bristol-Myers Squibb Co. (NYSE:BMY) and Norma Investments also participated, as did existing...
BC Week In Review | Jan 6, 2017
Clinical News

TAR-200: Preliminary Ph Ib data

Preliminary data from 10 patients with muscle invasive bladder cancer in an open-label, U.S. Phase Ib trial showed that TAR-200 inserted into the bladder during days 1-7 and days 21-28 following initial transurethral resection of...
BC Week In Review | Aug 15, 2016
Clinical News

GemRIS: Phase Ib started

Taris began an open-label, European Phase Ib trial to evaluate TAR-200 inserted into the bladder for 7 days at days 0 and 21 in up to 30 patients with intermediate-risk NMIBC before transurethral resection of...
BC Week In Review | Jul 25, 2016
Clinical News

GemRIS: Phase Ib started

Taris began an open-label, U.S. Phase Ib trial to evaluate TAR-200 inserted into the bladder for 7 days at days 0 and 21 in up to 20 patients before radical cystectomy. Taris Biomedical LLC , Lexington,...
BioCentury | Feb 22, 2016
Finance

Investing upstream

After a decade of focusing on public investments and later adding private investments to its remit, RA Capital is getting into the business of starting companies from whole cloth. The firm thinks having a dedicated...
BC Week In Review | Nov 2, 2015
Financial News

Taris Biomedical completes venture financing

Taris Biomedical LLC , Lexington, Mass.   Business: Cancer, Genitourinary, Drug delivery   Date completed: 2015-10-27   Type: Venture financing   Raised: $32 million   Investors: Flagship Ventures; Polaris Partners; RA Capital Management  ...
Items per page:
1 - 10 of 31